We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Myriad Genetics Gains on Innovation, New Reimbursements
Read MoreHide Full Article
On Mar 26, we issued an updated research report on Myriad Genetics, Inc. (MYGN - Free Report) . The stock carries a Zacks Rank #3 (Hold).
Shares of this Salt Lake City, UT-based molecular diagnostics provider have outperformed the broader industry over the past six months. The stock has rallied 19.2% compared with the industry’s 9.5% rise.
The company’s molecular-diagnostics portfolio has been gaining prominence in the MedTech space of late. We are particularly upbeat about its newly-launched product line. Myriad Genetics has been recording strong volumes of EndoPredict and GeneSight tests. In the Prolaris testing domain, volumes steadily expanded in double-digits during second-quarter fiscal 2019.
Particularly, Myriad Genetics is focused on driving revenues by commercializing its innovative products including Vectra DA, Prolaris, myPath Melanoma, Myriad Genetics’s Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test. Earlier, management expected each of the products to generate revenues of more than $50 million by fiscal 2020.
Moreover, Myriad Genetics has been consistently gaining reimbursement approvals. In the last reported quarter, the company announced the finalization of LCD (Local Coverage Determination) from Noridian for EndoPredict, thus extending the total coverage to around 90% of the U.S. market. Also, the Prolaris test is under evaluation by the revised NCCN (National Comprehensive Cancer Network) guidelines and has been covered by Medicare for the patients at intermediate risk.
Also, in order to gain reimbursement coverage on Vectra DA and GeneSight testing platforms, the company is constantly undertaking specific measures.
Meanwhile, Myriad Genetics faces stiff competition in the key BRACAnalysis market. The company expects the same to intensify due to the advancement of technology. We believe, tough headwinds might reduce the prices of expensive tests provided by the company. This might in turn, impede the stock’s margin improvement.
Moreover, as the company receives a considerable portion of its revenues as well as pays part of its expenses in foreign currencies, it is exposed to exchange rate fluctuations between foreign notes and the U.S. dollar.
Stryker’s long-term earnings growth rate is expected to be 10%
Penumbra’s long-term earnings growth rate is anticipated at 20.9%.
Varian’s long-term earnings growth rate is predicted to be 8%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Myriad Genetics Gains on Innovation, New Reimbursements
On Mar 26, we issued an updated research report on Myriad Genetics, Inc. (MYGN - Free Report) . The stock carries a Zacks Rank #3 (Hold).
Shares of this Salt Lake City, UT-based molecular diagnostics provider have outperformed the broader industry over the past six months. The stock has rallied 19.2% compared with the industry’s 9.5% rise.
The company’s molecular-diagnostics portfolio has been gaining prominence in the MedTech space of late. We are particularly upbeat about its newly-launched product line. Myriad Genetics has been recording strong volumes of EndoPredict and GeneSight tests. In the Prolaris testing domain, volumes steadily expanded in double-digits during second-quarter fiscal 2019.
Myriad Genetics, Inc. Price
Myriad Genetics, Inc. Price | Myriad Genetics, Inc. Quote
Particularly, Myriad Genetics is focused on driving revenues by commercializing its innovative products including Vectra DA, Prolaris, myPath Melanoma, Myriad Genetics’s Companion Diagnostics, EndoPredict and myPlan Lung Cancer Test. Earlier, management expected each of the products to generate revenues of more than $50 million by fiscal 2020.
Moreover, Myriad Genetics has been consistently gaining reimbursement approvals. In the last reported quarter, the company announced the finalization of LCD (Local Coverage Determination) from Noridian for EndoPredict, thus extending the total coverage to around 90% of the U.S. market. Also, the Prolaris test is under evaluation by the revised NCCN (National Comprehensive Cancer Network) guidelines and has been covered by Medicare for the patients at intermediate risk.
Also, in order to gain reimbursement coverage on Vectra DA and GeneSight testing platforms, the company is constantly undertaking specific measures.
Meanwhile, Myriad Genetics faces stiff competition in the key BRACAnalysis market. The company expects the same to intensify due to the advancement of technology. We believe, tough headwinds might reduce the prices of expensive tests provided by the company. This might in turn, impede the stock’s margin improvement.
Moreover, as the company receives a considerable portion of its revenues as well as pays part of its expenses in foreign currencies, it is exposed to exchange rate fluctuations between foreign notes and the U.S. dollar.
Key Picks
Some better-ranked stocks in the broader medical space are Stryker Corporation (SYK - Free Report) , Penumbra, Inc., (PEN - Free Report) and Varian Medical Systems, Inc . Notably, each currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Stryker’s long-term earnings growth rate is expected to be 10%
Penumbra’s long-term earnings growth rate is anticipated at 20.9%.
Varian’s long-term earnings growth rate is predicted to be 8%.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>